BioAtla (BCAB) Cash & Equivalents (2020 - 2026)

BioAtla's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 93.94% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (down 93.94% YoY), while the FY2025 annual figure was $7.1 million, down 85.49% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.0 million, down from $7.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $219.4 million in Q1 2022, with the low at $2.0 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $71.1 million (2024), against an average of $95.6 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents retreated 0.8% in 2022, then plunged 93.94% in 2026.
• BioAtla's Cash & Equivalents stood at $178.1 million in 2022, then plunged by 37.42% to $111.5 million in 2023, then slumped by 56.0% to $49.0 million in 2024, then plunged by 85.49% to $7.1 million in 2025, then tumbled by 72.45% to $2.0 million in 2026.
• Business Quant data shows BCAB's Cash & Equivalents at $2.0 million in Q1 2026, $7.1 million in Q4 2025, and $8.3 million in Q3 2025.